Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 and Ipamorelin UK 2026 Research Reference

CJC-1295 and Ipamorelin UK 2026 Research Reference Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. Overview — why CJC-1295 and ipamorelin are paired 2. Receptor pharmaco

By Recovery & Performance Peptides Editorial Team

CJC-1295 and Ipamorelin UK 2026 Research Reference

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

1. Overview — why CJC-1295 and ipamorelin are paired

2. Receptor pharmacology: two pathways, one outcome

3. CJC-1295 structure and DAC variant

4. Ipamorelin structure and selectivity

5. Synergy mechanism at the somatotroph

6. Pharmacokinetics compared

7. Combined protocol design

8. Preserving GH pulsatility — why it matters

9. Hormonal selectivity vs sermorelin and GHRP-6

10. Safety profile and side-effect signals

11. Reconstitution, storage and stability

12. Research applications

13. UK research-grade sourcing standards

FAQ

References

1. Overview — why CJC-1295 and ipamorelin are paired

The growth-hormone-secretagogue research space divides into two receptor classes: GHRH receptor (GHRHR) agonists and ghrelin receptor (GHSR-1a) agonists. Both classes stimulate GH release from anterior pituitary somatotrophs, but via distinct intracellular signalling pathways. The combined-stack rationale — GHRH analogue plus ghrelin receptor agonist — was established in the 1990s in studies using GHRH(1-29) plus GHRP-6 or hexarelin, which demonstrated supra-additive (not merely additive) GH release.

CJC-1295 and ipamorelin represent the modern selective versions of this combination: CJC-1295 is the most pharmacokinetically stable GHRH analogue, and ipamorelin is the most receptor-selective ghrelin-mimetic without cortisol or prolactin elevation. For UK laboratory research into growth-hormone pulse biology, IGF-1 induction, or somatotroph receptor pharmacology, this pair is the reference combination.

2. Receptor pharmacology: two pathways, one outcome

GHRH receptor (GHRHR): Class B GPCR, expressed primarily on anterior pituitary somatotrophs. Signals via Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → GH1 transcription and GH vesicle exocytosis. CJC-1295 binds here.

Ghrelin receptor (GHSR-1a): Class A GPCR, expressed on somatotrophs, hypothalamic neurons, and peripherally in gastric mucosa, pancreas, and cardiovascular tissue. Signals via Gαq → PLC → IP₃/DAG → Ca²⁺ release and PKC activation. Ipamorelin binds here.

At the somatotroph, GHRHR activation primarily drives transcriptional and secretory priming via cAMP, while GHSR-1a activation primarily drives immediate Ca²⁺-dependent exocytosis. Co-activation produces GH pulses with both larger amplitude and greater secretory reserve than either pathway alone.

3. CJC-1295 structure and DAC variant

CJC-1295 is derived from human GHRH(1-29), the smallest biologically active fragment of GHRH. Four amino acid substitutions (D-Ala²→stabilise N-terminus against DPP-4; Gln⁸, Ala¹⁵, Leu²⁷) confer increased intrinsic stability and receptor affinity.

CJC-1295 “no DAC” (also called Modified GRF 1-29, mod-GRF 1-29): The 29-amino-acid peptide alone. Half-life approximately 30 minutes. Produces rapid, defined GH pulses. Preserves physiological pulsatility when dosed 1-3× daily.

CJC-1295 “with DAC”: Adds a maleimidopropionyl-lysine tail that reacts covalently with circulating albumin in plasma. The albumin conjugate has a half-life of approximately 8 days. Produces sustained GHRH-receptor activation. Does not preserve pulsatility — somatotroph stimulation is tonic.

Research protocols that aim to model physiological GH release use CJC-1295 no-DAC; protocols that aim to produce sustained elevation of IGF-1 or model pharmacological overdrive use CJC-1295 with DAC.

4. Ipamorelin structure and selectivity

Ipamorelin is a pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — designed at Novo Nordisk in the 1990s as a selective ghrelin receptor agonist without cross-reactivity at the receptors responsible for cortisol and prolactin release.

Key pharmacological features:

GHSR-1a selectivity: comparable GH-releasing potency to hexalrelin and GHRP-6 but without the cortisol, ACTH or prolactin elevation those peptides produce

Half-life: approximately 2 hours (plasma)

No appetite stimulation at standard research doses (unlike GHRP-6, which is a potent orexigen via the hypothalamic ghrelin circuit)

No significant effect on insulin sensitivity at research doses

Ipamorelin’s clean selectivity profile is the reason it is the preferred ghrelin-mimetic for research stacks — it isolates the ghrelin-receptor contribution to GH release without confounding effects on the HPA axis or lactotrophs.

5. Synergy mechanism at the somatotroph

Co-administration of GHRH analogue plus ghrelin-receptor agonist produces 2-5× greater peak GH release than the sum of each peptide alone. The mechanism involves:

Converging second-messenger pathways: cAMP (from GHRHR) and Ca²⁺ (from GHSR-1a) both potentiate GH vesicle exocytosis; their convergence is synergistic, not additive.

Suppression of somatostatin: GHSR-1a activation at hypothalamic sites suppresses periventricular somatostatin neurons, removing the tonic brake on GH release. CJC-1295 alone does not do this.

Priming of somatotroph secretory reserve: CJC-1295’s cAMP signalling increases GH1 transcription and vesicle loading; subsequent ipamorelin-driven exocytosis releases this larger reserve.

The practical research consequence: a combined protocol produces not only larger but more reproducible GH pulses than either peptide alone.

6. Pharmacokinetics compared

CJC-1295 no-DAC (mod-GRF 1-29):

Molecular weight: 3367.91 Da (30 aa after modifications including C-terminal NH₂)

Half-life: 25-30 min (SC)

Tmax: 10-20 min

Duration of GH-releasing effect: 60-90 min

CJC-1295 with DAC:

Molecular weight: 3647.20 Da (as synthesised); effective MW as albumin-DAC conjugate ~70,000 Da

Half-life: ~8 days (as albumin conjugate)

Steady-state reached: 3-4 weeks of weekly dosing

Duration of GH-releasing effect: continuous at steady state

Ipamorelin:

Molecular weight: 711.86 Da (pentapeptide + N-terminal Aib)

Half-life: 2 hours

Tmax: 15-30 min SC

Duration of GH-releasing effect: 2-3 hours

7. Combined protocol design

Standard UK laboratory research protocols using the CJC-1295 + ipamorelin combination fall into two designs:

Pulsatile design (no-DAC + ipamorelin):

CJC-1295 no-DAC: 100 µg SC

Ipamorelin: 100-200 µg SC

Timing: co-administered, 1-3× daily

Typical pattern: morning, mid-afternoon, and/or pre-bed

Duration: 8-12 week study blocks

Rationale: models physiological pulsatile GH release with amplified pulses

Sustained design (with-DAC + ipamorelin):

CJC-1295 with DAC: 1-2 mg SC weekly

Ipamorelin: 200-300 µg SC, 1-3× daily

Rationale: sustained GHRH-receptor priming plus pulsatile ghrelin-receptor activation

Produces chronically elevated IGF-1 with retained pulse character

Dose-response data in healthy adults show approximately linear IGF-1 response up to CJC-1295 2 mg weekly; plateau above 2 mg. Ipamorelin dose-response plateaus at approximately 300 µg per administration.

8. Preserving GH pulsatility — why it matters

Physiological GH release is strongly pulsatile, with 5-8 pulses per 24 hours, peak concentrations during the first hours of sleep, and near-undetectable trough concentrations between pulses. The pulsatility itself is biologically important:

Downstream signalling (JAK2-STAT5, MAPK) is pulse-encoded; continuous GH signalling produces different transcriptional outputs than pulsatile signalling

Peripheral GH receptor sensitivity is maintained by trough periods; continuous stimulation produces receptor desensitisation

Sex-dimorphic gene expression in liver is pulsatility-dependent

Research designs that want to preserve these features use CJC-1295 no-DAC; designs that accept desensitisation as a variable or deliberately model pharmacological overdrive use CJC-1295 with DAC.

9. Hormonal selectivity vs sermorelin and GHRP-6

Sermorelin: GHRH(1-29), the unmodified native fragment. Half-life 10-20 minutes. No DAC variant. Largely superseded by CJC-1295 no-DAC in research use because the four CJC substitutions produce longer half-life and greater receptor affinity without loss of selectivity.

GHRP-6: First-generation ghrelin-receptor agonist. Potent GH releaser but also potent orexigen (strong appetite stimulation), moderate cortisol and prolactin elevation. Suitable for appetite research but inferior to ipamorelin for clean growth-hormone secretagogue studies.

GHRP-2: Intermediate selectivity — better than GHRP-6 but less selective than ipamorelin.

Hexarelin: Most potent ghrelin-receptor agonist but greatest cortisol and prolactin cross-reactivity. Declining use in contemporary research.

MK-677 (ibutamoren): Orally bioavailable non-peptide ghrelin-receptor agonist. Useful where oral administration is required; produces greater tonic activation than injectable ghrelin-mimetics. Covered in detail in a separate reference article.

10. Safety profile and side-effect signals

The combination is well-characterised in the research literature with a defined side-effect profile:

Injection-site reactions: 3-8%, typically mild erythema and transient induration

Transient hypoglycaemia: 1-3%, related to the post-pulse IGF-1 insulin-mimetic effect; mitigated by food near dosing

Transient fluid retention: 5-10%, peripheral oedema or mild facial fullness, usually resolves after 2-4 weeks of adaptation

Carpal tunnel symptoms: <5%, dose-related, reversible on dose reduction

Headache: 5-10%, typically transient at initiation

Injection-site lipohypertrophy: <1% with appropriate site rotation

Notable absences from the ipamorelin profile: cortisol elevation, prolactin elevation, significant appetite stimulation — the features that differentiate ipamorelin from GHRP-6 and hexarelin.

11. Reconstitution, storage and stability

CJC-1295 no-DAC (typical 2 mg vial): reconstitute with 2 mL bacteriostatic water → 1 mg/mL. At 100 µg per administration, 0.1 mL (10 units on an insulin syringe).

CJC-1295 with DAC (typical 2 mg vial): reconstitute with 2 mL bacteriostatic water → 1 mg/mL. At 1-2 mg weekly, 1-2 mL per dose.

Ipamorelin (typical 5 mg vial): reconstitute with 2.5 mL bacteriostatic water → 2 mg/mL. At 200 µg per administration, 0.1 mL (10 units).

All three peptides are stable after reconstitution at 2-8°C for 30-45 days. Protect from freezing and direct light. Do not mix in the same syringe with non-compatible co-formulations; co-administration is typically done as two separate injections at adjacent subcutaneous sites.

12. Research applications

Established UK laboratory research applications for the CJC-1295 + ipamorelin combination:

Pulsatile GH release dynamics and pulse-amplitude modelling

IGF-1 generation and time-course studies

Somatotroph receptor pharmacology, desensitisation and re-sensitisation kinetics

Sex-dimorphic GH pulse pattern studies in preclinical models

Hypothalamic-pituitary axis GH-branch stimulation tests

Benchmarking arm in novel growth-hormone-secretagogue compound development

Tissue-specific IGF-1 response studies (hepatic, muscle, cartilage)

Body-composition research in rodent and non-human primate models

13. UK research-grade sourcing standards

Both peptides should be sourced with full documentation:

≥98% HPLC purity (≥99% is the emerging 2026 standard)

Mass spectrometry identity confirmation (CJC-1295 no-DAC 3367.91 Da; CJC-1295 with-DAC 3647.20 Da; ipamorelin 711.86 Da)

Batch-specific Certificate of Analysis

Endotoxin quantification

Residual TFA analysis

Lyophilised powder with cold-chain shipping

A quality-control specific note for CJC-1295 with DAC: the maleimidopropionyl-lysine tail is the most difficult synthetic step and the most common site of batch-to-batch variance. A high-quality COA should specifically confirm DAC attachment yield and absence of des-DAC parent peptide.

FAQ

Should I use CJC-1295 with or without DAC? Use no-DAC to preserve pulsatility and model physiological GH release; use with-DAC to produce sustained IGF-1 elevation. Most UK laboratory protocols default to no-DAC because pulsatility is biologically relevant.

Is the synergy real? Yes. Paired-dose studies consistently show 2-5× greater GH pulse amplitude than either peptide alone, confirmed across healthy adult and preclinical cohorts since the late 1990s.

Does ipamorelin elevate cortisol? No, at standard research doses. Ipamorelin was specifically designed to lack the cortisol and prolactin cross-reactivity of GHRP-6. In direct head-to-head studies, ipamorelin produces no significant elevation of cortisol or prolactin even at supra-physiological GH-releasing doses.

Does ipamorelin cause appetite stimulation? No, at standard research doses. This differentiates it sharply from GHRP-6.

How long before IGF-1 elevation is measurable? With a pulsatile protocol: IGF-1 begins to rise within 48-72 hours; stable elevation by 2-3 weeks. With DAC protocol: similar time course but larger magnitude.

Is there a tachyphylaxis issue? Mild. Over 8-12 weeks of continuous dosing, GH pulse amplitude per administration decreases approximately 20-30%. Cycling protocols (8 weeks on, 4 weeks off) are commonly used to preserve somatotroph responsiveness.

Can the pair be combined with tesamorelin or sermorelin? Mechanistically redundant with tesamorelin and sermorelin (all three are GHRHR agonists). No added benefit expected. The rational combinations are CJC-1295 (or tesamorelin, or sermorelin) + ipamorelin (or another ghrelin-mimetic).

References

Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006;91:799–805.

Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561.

Jimenez-Reina L et al. In vitro effects of ghrelin and GHRP-6 on somatotroph GH secretion. Endocrinology 2003;144:3336–3344.

Bowers CY. History of the development of GH-releasing peptides and analogues. Growth Horm IGF Res 2012;22:221–231.

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone induced by the combination of a GH-releasing peptide and a GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792–4797.

Khorram O et al. Effects of aging on the pulsatile secretion of growth hormone and its response to GHRH. J Clin Endocrinol Metab 1997;82:1472–1479.

Kineman RD et al. Understanding the physiology of growth hormone-releasing hormone and growth hormone-releasing peptide action. Front Endocrinol 2011;2:24.

Howard AD et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974–977.

Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998;19:47–72.

Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.

UK Research Cluster Hubs

GLP-1 Research Hub

Tirzepatide Hub

Retatrutide Hub

BPC-157 Research Hub

TB-500 Research Hub

Growth-Hormone Peptides Hub

Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Optimal Dosing and Incubation Protocols for CJC-1295 In Vitro Research

Dose selection in CJC-1295 in vitro research must account for two variables most protocols ignore: albumin concentration in the culture media and the assay endpoint's time scale. The EC50 (half-maximal effective concentration) for CJC-1295 at the GHRH receptor is approximately 0.2–0.5 nM in cell-free receptor binding assays, but in whole-cell systems with 10% fetal bovine serum, the apparent EC50 shifts to 5–10 nM because albumin binding reduces free peptide availability. Standard practice uses a 10-point dose range from 0.01 nM to 100 nM to capture both baseline receptor occupancy and maximal response. But if your research question concerns physiological relevance, doses above 50 nM produce receptor saturation that never occurs in vivo even with therapeutic dosing. Incubation duration determines whether you're measuring acute receptor activation or sustained GH secretion. For cAMP accumulation assays, peak response occurs 10–15 minutes post-treatment; extending incubation beyond 30 minutes adds no additional signal because phosphodiesterases degrade cAMP as quickly as it's produced. For GH secretion, the relevant window is 24–72 hours. CJC-1295's DAC modification maintains receptor occupancy long enough to produce multiple secretory pulses in vitro, which short-duration assays miss entirely. A 2017 study in Endocrine Research demonstrated that cumulative GH secretion over 48 hours with CJC-1295 at 10 nM exceeded single-timepoint measurements at 6 hours by 3.2-fold, even tho…
STORAGE

Reconstitution and Storage: Essential Steps for Researchers

Handling peptides correctly after they arrive is absolutely critical for maintaining their stability and efficacy. We've seen promising research derailed by improper reconstitution or storage, and it's a frustrating, preventable setback. For any CJC-1295 beginners guide, this section is indispensable. When you receive your lyophilized (freeze-dried) CJC-1295, it's a stable powder. However, once you reconstitute it, things change. Reconstitution typically involves mixing the peptide powder with a sterile diluent, most commonly Bacteriostatic Reconstitution Water (bac). It's crucial to use the correct amount of diluent to achieve your desired concentration, and to do so gently. We recommend slowly adding the water down the side of the vial, then allowing it to dissolve naturally without vigorous shaking, which can degrade the peptide structure. This approach (which we've refined over years) delivers real results. Once reconstituted, CJC-1295 becomes much more fragile. It must be stored refrigerated, typically at 2-8°C (36-46°F), and kept away from light. Freezing can sometimes extend its lifespan further, but repeated freeze-thaw cycles are generally detrimental. Our team advises researchers to reconstitute only what they need for a specific period and to discard any unused portions after a recommended timeframe, usually a few weeks to a month, depending on the specific peptide and storage conditions. This meticulous approach ensures the integrity of your research material, ma…
02

Question drills

Open a question for its connected answer.

01What If the Peptide Dissolves But Looks Slightly Cloudy?+

Discard it immediately and do not proceed with injection. Cloudiness indicates either particulate contamination (bacterial, fungal, or foreign matter) or incomplete dissolution caused by degraded protein aggregates. Authentic CJC-1295 produces a solution indistinguishable from sterile water when properly reconstituted. Any visible haze means the vial is compromised. Attempting to filter the solution does not solve the problem because molecular degradation cannot be reversed, and bacterial contamination may include endotoxins that pass through standard filters.

SOURCE / realpeptides.co ↗
02What If a Research Subject Uses CJC-1295 Without Adjusting Caloric Intake?+

Expect elevated serum GH and free fatty acids with minimal fat mass reduction. Growth hormone increases lipolysis, but without increased oxidative demand or reduced intake, released fatty acids recirculate and re-store. A 2021 pilot study found subjects using CJC-1295 ad libitum (no dietary restriction) showed no significant body composition changes over 8 weeks despite 240% higher mean GH levels. The peptide creates metabolic flexibility but doesn't force substrate utilization. Protocols designed to study fat loss must include structured caloric prescription. CJC-1295 enhances outcomes within deficit states, it doesn't replace them.

SOURCE / realpeptides.co ↗
03What If Recovery Results Appear Slower Than Expected After Four Weeks?+

Verify dosing accuracy and reconstitution protocol first. CJC-1295 (DAC) is typically dosed at 1–2mg per week; underdosing below 0.5mg weekly produces subtherapeutic IGF-1 elevation. Reconstitution with bacteriostatic water must preserve sterility. Contamination or improper pH can denature the peptide structure, rendering it inactive despite correct dosing volume. If dosing is confirmed accurate, assess training stimulus and protein intake. IGF-1 signaling is permissive, not causative; without adequate mechanical tension (resistance training) or substrate availability (1.6–2.2g protein per kg body weight), downstream anabolic pathways remain unstimulated even with elevated IGF-1.

SOURCE / realpeptides.co ↗
04What If You Miss a Scheduled Twice-Weekly Dose?+

If fewer than 48 hours have passed since the missed dose, administer immediately and resume the standard schedule. If more than 48 hours have passed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to

SOURCE / realpeptides.co ↗
05What If I Left Unreconstituted CJC-1295 Out for 24 Hours?+

Return it to −20°C or 2–8°C storage immediately. Lyophilized peptides tolerate brief thermal excursions. One 24-hour room-temperature event causes <5% potency loss in most cases. The peptide remains viable for research use. Avoid repeated freeze-thaw cycles: if you're storing at −20°C, leave the vial frozen until you're ready to reconstitute. Multiple temperature swings compound degradation risk even in lyophilized form.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

The Criticality of Purity in Peptide Research

We can't stress this enough: when exploring CJC-1295 science explained, the purity and quality of your research materials are absolutely paramount. Low-purity peptides, or those with incorrect amino-acid sequencing, can lead to inaccurate, irreproducible, and frankly, catastrophic research outcomes. It's becoming increasingly challenging to find reliable suppliers in a market flooded with varying quality. At Real Peptides, our unwavering commitment to precision and quality defines everything we do. We understand that your research hinges on the reliability of our products. That's why every peptide, including our CJC-1295 + Ipamorelin (5mg/5mg) and CJC 1295 (no Dac), is crafted through small-batch synthesis with exact amino-acid sequencing. We're talking about rigorous testing and transparent reporting, ensuring you receive only the highest-purity, research-grade compounds. Our reputation, and more importantly, your research integrity, depends on it. We mean this sincerely: it runs on genuine connections and impeccable quality control. This meticulous process guarantees purity, consistency, and lab reliability – every single time. It's not just a claim; it's a foundational principle of our company, which you can further explore by visiting our website at Real Peptides. We believe that providing superior quality materials is the bedrock upon which all groundbreaking discoveries are built. Without it, your understanding of CJC-1295 science explained remains incomplete, potentially flawed.

RESEARCH

The Inconvenient Truth About CJC-1295 for Researchers in Their 30s

Here's the honest answer: most researchers in their 30s don't need CJC-1295 yet. Your endogenous GH secretion is still 75–85% of peak capacity. The decline is real but not profound enough to justify exogenous GHRH analog intervention unless baseline IGF-1 is demonstrably low (<150ng/mL) or you're recovering from metabolic suppression (post-diet, chronic sleep deprivation, overtraining). The peptide works, but it's solving a problem that for most people under 40 is minor at best. If your IGF-1 is already 220–250ng/mL, CJC-1295 will push it to 270–300ng/mL. An incremental gain that matters far less than fixing sleep quality, protein intake, or training programming. The real value of age-specific protocols at this stage isn't maximizing IGF-1. It's establishing a baseline and learning how your body responds to GHRH stimulation before the decline accelerates in your 40s and 50s. Running a conservative 8-week cycle with proper monitoring teaches you what dosing works, what side effects to expect, and whether you're a strong responder or someone who needs higher doses to see results. That knowledge compounds over time. But if you're chasing the peptide as a shortcut around suboptimal training or nutrition, it won't deliver. CJC-1295 amplifies your existing GH pulse pattern. It doesn't create one from scratch.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 (No DAC) vs. CJC-1295 with DAC: A Critical Comparison

Understanding the fundamental differences between CJC-1295 (no DAC) and CJC-1295 with DAC is absolutely crucial for any researcher venturing into CJC-1295 sustained GH therapy. Wh…

Continue reading

Related articles